在心脏和糖尿病设备销售强劲的驱动下,Medtronic击败了对2026年Q3的利润预期,并重申其2026年的收入前景。 Medtronic beat profit expectations in Q3 2026, driven by strong heart and diabetes device sales, and reaffirmed its 2026 earnings outlook.

美敦力第三季度利润超出预期，非GAAP每股收益为1.36美元，主要得益于心脏器械和糖尿病监测器的强劲销售。 Medtronic surpassed third-quarter profit expectations with non-GAAP earnings of $1.36 per share, driven by strong sales in heart devices and diabetes monitors. 收入达到90.2亿美元,有机增长6%,由心脏通缩解决方案增长80%和137%的美国销售激增所推动。 Revenue reached $9.02 billion, up 6% organically, fueled by 80% growth in cardiac ablation solutions and 137% U.S. sales surge. 该公司获得了FDA和CE对新手术系统的批准,推进了其并购战略,并重申了其2026年5.62美元至5.66美元的调整EPS的前景. The company secured FDA and CE approvals for new surgical systems, advanced its M&A strategy, and reaffirmed its 2026 outlook for $5.62 to $5.66 in adjusted EPS.